L1 mutagenesis for mammalian models of human diseases

Information

  • Research Project
  • 6883346
  • ApplicationId
    6883346
  • Core Project Number
    R43RR021289
  • Full Project Number
    1R43RR021289-01
  • Serial Number
    21289
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/14/2005 - 20 years ago
  • Project End Date
    1/31/2006 - 19 years ago
  • Program Officer Name
    RALL, WILLIAM F.
  • Budget Start Date
    2/14/2005 - 20 years ago
  • Budget End Date
    1/31/2006 - 19 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/11/2005 - 20 years ago

L1 mutagenesis for mammalian models of human diseases

[unreadable] DESCRIPTION (provided by applicant): Transposagen is developing an innovative mammalian random mutagenesis system that uses an L1 retrotransposon for direct germ-line mutagenesis. Transposagen's goal is to produce "mutator rats". In these rats, mutagensis will occur in sperm and some offspring will contain single gene disruptions. We will use the mouse to optimize and validate our system because of the much higher cost in producing transgenic rats. We have developed "mutator mice" containing a marked L1 transgene capable of germ-line insertional mutagenesis. The focus of this proposal is to validate the Transposagen random mutagenesis system as a tool for functional genomics. Phase I of this project includes characterization of the mutator mice. Specific aim 1 is to determine the frequency of insertional mutagenesis in the sperm of mutator mice. Specific aim 2 is to determine the percentage of insertions that insert into genes. Specific aim 3 is to determine the efficiency of gene disruption. Phase II of the project will use the information gained from the Phase I mouse studies to create mutator rats. L1 elements are present in all mammals and a human L1 element is capable of high-level retrotransposition in human, mouse, hamster, feline, and even quail cells. Therefore, our findings in mice from this study should extrapolate directly to rats. Transposagen's random mutagenesis system could utlimately be adapted for use in any mammal. Mutator mice and rats will substantially aid drug discovery programs by producing animal models for new drug targets. [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R43
  • Administering IC
    RR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99724
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:99724\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    145182338
  • Organization City
    Lexington
  • Organization State
    KY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191042853
  • Organization District
    UNITED STATES